Skip to main navigation Skip to search Skip to main content

Current use and developments needed for optimal design in pharmacometrics: A study performed among ddmore's european federation of pharmaceutical industries and associations members

  • F. Mentré
  • , M. Chenel
  • , E. Comets
  • , J. Grevel
  • , A. Hooker
  • , M. O. Karlsson
  • , M. Lavielle
  • , I. Gueorguieva
  • UMR 738
  • INSERM U869
  • Clinical Pharmacokinetic Department
  • Institut de Recherches Internationales Servier
  • BAST Inc. Limited
  • Uppsala University
  • INRIA Institut National de Recherche en Informatique et en Automatique
  • Global PK/PD Department

Research output: Contribution to journal › Review article › peer-review

29 Citations (Scopus)

Abstract

Methods and software tools for optimal design in nonlinear mixed effect models, based on the Fisher information matrix, have been developed for a decade.1,2 Academic groups regularly proposed new versions.3-5 Present tools do not incorporate adaptive designs for these models although prior information is needed and adaptive designs are increasingly used in drug development.6 We conducted a study among drug companies of the Drug and Disease Model Resources consortium7 to identify current practices and expectations.

Original languageEnglish
Article numbere46
JournalCPT: Pharmacometrics and Systems Pharmacology
Volume2
Issue number6
DOIs
Publication statusPublished - 1 Jun 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'Current use and developments needed for optimal design in pharmacometrics: A study performed among ddmore's european federation of pharmaceutical industries and associations members'. Together they form a unique fingerprint.

Cite this